9.54

17.40% -2.01

After Hours: 9.56 0.02 +0.21%

Immunitybio Inc (IBRX)

Overview News Price History Option Chain Financials Why IBRX Down? Discussions Forecast

Immunitybio Inc stock is traded at $9.54, with a volume of 80.22M. It is down -17.40% in the last 24 hours and up +47.91% over the past month. ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Previous Close:

$11.55

Open:

$12.17

24h Volume:

80.22M

Relative Volume:

2.56

Market Cap:

$9.40B

Revenue:

$1.31M

Net Income/Loss:

$-597.65M

P/E Ratio:

-9.8351

EPS:

-0.97

Net Cash Flow:

$-425.62M

1W Performance:

+11.71%

1M Performance:

+47.91%

6M Performance:

+324.00%

1Y Performance:

+214.85%

1-Day Range:

$9.38

$12.43

1-Week Range:

$7.60

$12.43

52-Week Range:

$1.83

$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name

Immunitybio Inc

Sector

Healthcare (1108)

Industry

Biotechnology (621)

Phone

(844) 696-5235

Address

3530 JOHN HOPKINS COURT, SAN DIEGO

Employee

673

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IBRX Immunitybio Inc	9.54	11.38B	1.31M	-597.65M	-425.62M	-0.97
VRTX Vertex Pharmaceuticals Inc	483.05	123.82B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	784.28	81.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	816.95	52.00B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	327.36	44.14B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	352.23	40.83B	4.98B	69.60M	525.67M	0.5198

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Mar-06-25	Initiated	H.C. Wainwright	Buy
Jan-10-25	Initiated	BTIG Research	Buy
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-03-22	Initiated	Jefferies	Buy

Immunitybio Inc (IBRX)

Immunitybio Inc Stock (IBRX) Company Profile

Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Immunitybio Inc Stock (IBRX) Latest News

ImmunityBio Stock Is Up 18% This Week: Here’s What Global ANKTIVA Approvals Mean - TIKR.com

IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN

Dr. Patrick Soon-Shiong will participate as a speaker at the "Cancer 2035: A Roadmap for the Future" - Oncodaily

Why ImmunityBio Stock Is Soaring Today - AOL.com

ImmunityBio Supersedes Expectations With Fivefold Revenue IncreaseImmunityBio (NASDAQ:IBRX) - Benzinga

ImmunityBio Stock (IBRX) Opinions on Saudi Launch and EU Approval - Quiver Quantitative

ImmunityBio Faces Intense Scrutiny as Legal Concerns Mount - timothysykes.com

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate - Finviz

ImmunityBio Shares Surge on Stellar Revenue Growth and Regulatory Milestones - AD HOC NEWS

ImmunityBio Surges as Anktiva Drives 671% Revenue Growth - Tokenist

ImmunityBio: Disconnect Between Clinical Progress And Stock Performance (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus - TechStock²

ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption - Finviz

ImmunityBio (IBRX) Revenue Ramp To US$38 Million Tests Profitability Optimism - simplywall.st

IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook - Meyka

ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump - Insider Monkey

ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits

ImmunityBio, Inc. (IBRX): Harnessing a 407% Revenue Growth with a Promising 28% Upside Potential - DirectorsTalk Interviews

Selecky of Immunitybio sells $250,000 in shares - Investing.com

Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million - Investing.com

IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move - Stocktwits

Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million By Investing.com - Investing.com Nigeria

Selecky of Immunitybio sells $250,000 in shares By Investing.com - Investing.com Nigeria

ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN

ImmunityBio's Anktiva Drives Record Revenue Amid Global Expansion Push - AD HOC NEWS

ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity - Yahoo Finance

ImmunityBio (IBRX) Stock Explodes 500%+ in 2026 on ANKTIVA's 700% Revenue Surge - International Business Times Australia

ImmunityBio Expands Reach: ANKTIVA Gains Conditional EU Approval - StocksToTrade

European Nod Boosts ImmunityBio’s Market Presence - timothysykes.com

ImmunityBio reports $113M in ANKTIVA sales, up 700% in 2025 - Investing.com India

Goldman Sachs, H.C. Wainwright Maintain Buy on ImmunityBio, Inc. (IBRX) Feb 2026 - Meyka

Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits

Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight - GuruFocus

IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth - Stocktwits

Why ImmunityBio (IBRX) Is Up 65.3% After ANKTIVA’s European Approval And New Regional Partnerships - simplywall.st

IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans, hints at cancer breakthrough - MSN

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit - Investing News Network

IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundatio - PharmiWeb.com

ImmunityBio, Inc. SEC 10-K Report - TradingView

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% - Yahoo Finance

IMMUNITYBIO ($IBRX) Releases Q4 2025 Earnings - Quiver Quantitative

H.C. Wainwright raises Immunitybio stock price target to $15 By Investing.com - Investing.com India

H.C. Wainwright raises Immunitybio stock price target to $15 - Investing.com India

Why ImmunityBio stock is soaring again today - MSN

ImmunityBio Shares Rise After Q4 Results - marketscreener.com

Why ImmunityBio Stock Is Soaring Again Today - Yahoo Finance

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth - Bitget

ImmunityBio Shares Surge On 700% Revenue Growth Driven By AnktivaImmunityBio (NASDAQ:IBRX) - Benzinga

ImmunityBio Expands EU Market Presence with ANKTIVA Approval - StocksToTrade

ImmunityBio, Inc. (IBRX) Stock: Surges 15% as ANKTIVA Revenue Jumps 700% in 2025 - CoinCentral

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to IBRX